• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Chan Zuckerberg Initiative to acquire AI startup Meta

Chan Zuckerberg Initiative to acquire AI startup Meta

January 24, 2017
CenterWatch Staff

iGan Partners is thrilled to announce the pending acquisition of its portfolio company, Meta, by the Chan Zuckerberg Initiative. Launched in 2015 by Mark Zuckerberg and Dr. Priscilla Chan, the Chan Zuckerberg Initiative is dedicated to advancing human potential and promoting equal opportunity, with a current focus on scientific research, education, and building strong communities. The goal of their science initiative is to cure, prevent, or manage all diseases by the end of this century.

Meta is Toronto-based technology company that helps researchers understand what is happening globally in science, and shows them where science is headed. Meta uses artificial intelligence to read the world's scientific papers, understand what is in them, and deliver their insights to researchers in real time. This information can help researchers and experts make faster progress in all areas of science to accelerate medical advances.

As part of the Chan Zuckerberg Initiative, Meta's capabilities will get united into a single, powerful tool, and be made available to the entire scientific community. The Chan Zuckerberg Initiative and Meta are committed to offering these tools for free to all researchers.

 "We are very pleased to have supported Meta from the beginning and through the ups and downs of a startup. We believe the Chan Zuckerberg Initiative is the perfect home for Meta and it will form the backbone of the Chan Zuckerberg Initiative's goal to make a dent on disease. We will miss the regular interactions with Sam Molyneux and his team," said Sam Ifergan, president of iGan Partners.

"We are very excited about what lies ahead," said Sam Molyneux, co-founder and CEO of Meta. "Our progress was only possible due to the team, our board, the support of their families and friends, our investors, and the Canadian start-up system."

Meta's earliest backers include iGan Partners who led the seed round and has participated in every financing since. Other investors include Rho Canada Ventures, Solina Chau (Horizons Ventures), Everline Investments and many angels.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing